Andere Kunden interessierten sich auch für
![Exploring Diversity, Equity, Inclusion, and Health Equity Commitments and Approaches by Health Organization C-Suites]( "Exploring Diversity, Equity, Inclusion, and Health Equity Commitments and Approaches by Health Organization C-Suites")
Exploring Diversity, Equity, Inclusion, and Health Equity Commitments and Approaches by Health Organization C-Suites17,99 €![Six Strategies to be a More Effective and Efficient Monitor: A practical personal approach to monitoring clinical trials]( "Six Strategies to be a More Effective and Efficient Monitor: A practical personal approach to monitoring clinical trials")
Six Strategies to be a More Effective and Efficient Monitor: A practical personal approach to monitoring clinical trials69,99 €![Ensuring an Effective Public Health Emergency Medical Countermeasures Enterprise]( "Ensuring an Effective Public Health Emergency Medical Countermeasures Enterprise")
Ensuring an Effective Public Health Emergency Medical Countermeasures Enterprise40,99 €![Public Engagement and Clinical Trials]( "Public Engagement and Clinical Trials")
Public Engagement and Clinical Trials46,99 €![Developing a National Registry of Pharmacologic and Biologic Clinical Trials]( "Developing a National Registry of Pharmacologic and Biologic Clinical Trials")
Developing a National Registry of Pharmacologic and Biologic Clinical Trials48,99 €![Envisioning a Transformed Clinical Trials Enterprise in the United States]( "Envisioning a Transformed Clinical Trials Enterprise in the United States")
Envisioning a Transformed Clinical Trials Enterprise in the United States54,99 €![Assuring Data Quality and Validity in Clinical Trials for Regulatory Decision Making]( "Assuring Data Quality and Validity in Clinical Trials for Regulatory Decision Making")
Assuring Data Quality and Validity in Clinical Trials for Regulatory Decision Making52,99 €
Even as the U.S. population becomes steadily more diverse, minorities and women remain underrepresented in clinical trials to develop new drugs and medical devices. Although progress in increasing minority participation in clinical trials has occurred, participation rates do not fully represent the overall population of minorities in the United States. This underrepresentation threatens the health of both these populations and the general population, since greater minority representation could reveal factors that affect health in all populations. Federal legislation has sought to increase the representation of minorities and women in clinical trials, but legislation by itself has not been sufficient to overcome the many barriers to greater participation. Only much broader changes will bring about the meaningful participation of all population groups in the clinical research needed to improve health. To examine the barriers to participation in clinical trials and ways of overcoming those barriers, the National Academies of Sciences, Engineering, and Medicine held a workshop in April 2015. This publication summarizes the presentations and discussions from the workshop.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.